Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2

Interventions

HhAntag691 14sonidegib 4methyl 5-aminolevulinate 3Photochemotherapy 3Aminolevulinic Acid 3tazarotene 2cemiplimab 2IPI-926 2Drug Evaluation 21-phenyl-3,3-dimethyltriazene 2silmitasertib 1remetinostat 1prednylidene 1pembrolizumab 1deltacortene 1Tacrolimus 1Risk Factors 1Prednisone 1Nivolumab 1NVP-BKM120 1Mohs Surgery 1Mindfulness 1Midazolam 1Itraconazole 1Ipilimumab 1IFL protocol 1Folfox protocol 1Fluorouracil 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Basal Cell × IPI-926 × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡